PMC5766284_01
Serial CT Monitoring. Complete regression of right facial tumor invading right orbit and cavernous sinus (red circles) documented on serial CT examination at baseline (a), 1 1/2 months (b), 3 1/2 months (c), 8 1/2 months (d), and 11 1/2 months. Right eye reduction (green arrows) back into orbit demonstrates gross effects of successful tumor shrinkage.
nihms856159f1.jpg
PMC5766284_01_nihms856159f1.jpg
F1
Baseline CT scan demonstrated an extensive primary lesion (39x24x22 mm), Figure 1a, invading the orbit with involvement of the superior and lateral orbital walls and posterior extension into the cavernous sinus.
Clinical Progress. Cutaneous SCC regression changes observed on clinical follow-up from baseline at start of prembolizumab (a), 2 1/2 months of treatment (b), and 10 months of treatment (c).
nihms856159f2.jpg
PMC5766284_01_nihms856159f2.jpg
F2
Superficial lesion regression, Figure 2, was also documented on routine clinical visits.